share_log

6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease

6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease

葛蘭素史克公司的RSV疫苗Arexvy獲得歐洲藥品管理局CHMP的積極評價,適用於50-59歲患RSV疾病風險較高的成年人
美股sec公告 ·  07/29 06:19
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息